{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:12:59Z","timestamp":1714349579021},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,27]]},"DOI":"10.7759\/cureus.59172","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T03:14:07Z","timestamp":1714274047000},"source":"Crossref","is-referenced-by-count":0,"title":["From 60% to 5% in 12 Weeks: A Trastuzumab-Induced Left Ventricular Ejection Fraction Drop"],"prefix":"10.7759","author":[{"given":"Qianjun","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzette","family":"Graham-Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano JL","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al.. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016, 37:2768-801. 10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0797-x","article-title":"Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study","volume":"33","author":"Hamirani Y","year":"2016","unstructured":"Hamirani Y, Fanous I, Kramer CM, Wong A, Salerno M, Dillon P. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Med Oncol. 2016, 33:82. 10.1007\/s12032-016-0797-x","journal-title":"Med Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: what the cardiologist needs to know","volume":"7","author":"Ewer MS","year":"2010","unstructured":"Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010, 7:564-75. 10.1038\/nrcardio.2010.121","journal-title":"Nat Rev Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614529603","article-title":"Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors","volume":"5","author":"Onitilo AA","year":"2014","unstructured":"Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 2014, 5:154-66. 10.1177\/2042098614529603","journal-title":"Ther Adv Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-induced cardiovascular disease: review of an underrecognized pathology","volume":"10","author":"Belzile-Dugas E","year":"2021","unstructured":"Belzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: review of an underrecognized pathology. J Am Heart Assoc. 2021, 10:e021686. 10.1161\/JAHA.121.021686","journal-title":"J Am Heart Assoc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter TM","year":"2013","unstructured":"Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013, 34:1102-11. 10.1093\/eurheartj\/ehs181","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter TM","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ, et al.. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007, 25:3859-65. 10.1200\/JCO.2006.09.1611","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Omland T","year":"2022","unstructured":"Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2022, 4:19-37. 10.1016\/j.jaccao.2022.01.101","journal-title":"JACC CardioOncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer MS","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005, 23:7820-6. 10.1200\/JCO.2005.13.300","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20910","article-title":"Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients","volume":"34","author":"Dichtl W","year":"2011","unstructured":"Dichtl W, Wolber T, Paoli U, et al.. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. Clin Cardiol. 2011, 34:433-6. 10.1002\/clc.20910","journal-title":"Clin Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.2000.tb00878.x","article-title":"Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers","volume":"23","author":"Sears SF","year":"2000","unstructured":"Sears SF, Todaro JF, Urizar G, et al.. Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol. 2000, 23:939-45. 10.1111\/j.1540-8159.2000.tb00878.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa054","article-title":"Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada","volume":"112","author":"Rushton M","year":"2020","unstructured":"Rushton M, Lima I, Tuna M, et al.. Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada. J Natl Cancer Inst. 2020, 112:1222-30. 10.1093\/jnci\/djaa054","journal-title":"J Natl Cancer Inst"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.04.005","article-title":"Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice","volume":"52","author":"Bouwer NI","year":"2020","unstructured":"Bouwer NI, Jager A, Liesting C, et al.. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice. Breast. 2020, 52:33-44. 10.1016\/j.breast.2020.04.005","journal-title":"Breast"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1910841","article-title":"Herceptin-mediated cardiotoxicity: assessment by cardiovascular magnetic resonance","volume":"2022","author":"Jiang J","year":"2022","unstructured":"Jiang J, Liu B, Hothi SS. Herceptin-mediated cardiotoxicity: assessment by cardiovascular magnetic resonance. Cardiol Res Pract. 2022, 2022:1910841. 10.1155\/2022\/1910841","journal-title":"Cardiol Res Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/244538-from-60-to-5-in-12-weeks-a-trastuzumab-induced-left-ventricular-ejection-fraction-drop","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T03:14:11Z","timestamp":1714274051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/244538-from-60-to-5-in-12-weeks-a-trastuzumab-induced-left-ventricular-ejection-fraction-drop"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.59172","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,27]]}}}